In Search Of Risk-Sharing Partners In China, India, Pharma Says
This article was originally published in PharmAsia News
Executive Summary
SAN FRANCISCO - Cost relief in China and India is paying off for big pharma, which is scrambling for pipelines in a world where in-license deals become ever less practical
You may also be interested in...
Asia Partnerships Critical To Big Pharma’s Drying Pipelines, Merck Exec Tells Bio Korea (Part 2 of 2)
[Editor's note: This is part two of a two-part story from Bio Korea; part one was published in PharmAsia News, Oct. 12, 2008.]
Asia Partnerships Critical To Big Pharma’s Drying Pipelines, Merck Exec Tells Bio Korea (Part 2 of 2)
[Editor's note: This is part two of a two-part story from Bio Korea; part one was published in PharmAsia News, Oct. 12, 2008.]
Covance R&D Deal Meshes With Lilly’s “FIPNet” Model
Lilly has deepened its commitment to its fully integrated pharmaceutical network strategy, most recently adding a deal with the contract research organization Covance